TY - CHAP
T1 - Drugs affecting muscle spasm and spasticity
AU - Benson, Andrew R.
AU - Stauffacher, Kelly A.
N1 - Publisher Copyright:
© 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins. All rights reserved.
Copyright:
Copyright 2016 Elsevier B.V., All rights reserved.
PY - 2012/11/7
Y1 - 2012/11/7
N2 - • Drugs used to manage muscle spasm and spasticity are divided into muscle relaxants and spasmolytics. Muscle spasm is a sudden, violent, involuntary contraction of a muscle or group of muscles. • Cyclobenzaprine (Flexeril) is the prototype for centrally acting muscle relaxants. • Centrally acting muscle relaxants do not act directly on painful muscles; rather, they work by their CNS depressant activity. • Most centrally acting muscle relaxants are not effective in treating spasticity. • In addition to their CNS depressant effects, centrally acting muscle relaxants have anticholinergic and antihistaminic effects. • Safety is a primary concern for patients receiving centrally acting muscle relaxants and spasmolytics. • Centrally acting muscle relaxants should be given with caution to older adults. They are not indicated for use in children. • Spasticity is a prolonged increased tone in muscles that may lead to contraction. • Baclofen (Lioresal) is the prototype centrally acting spasmolytic drug. • Gabapentin (Neurontin) is a miscellaneous antiepileptic drug that also has spasmolytic properties. • Dantrolene (Dantrium) is a peripherally acting spasmolytic that affects spasticity within the muscle fi bers. • Botulinum toxin type A (Botox) is used to manage chronic muscle spasms that do not respond to other treatment methods. It may also be used for cosmetic purposes. • Spasmolytics should be used cautiously in patients who require spasticity to remain upright.
AB - • Drugs used to manage muscle spasm and spasticity are divided into muscle relaxants and spasmolytics. Muscle spasm is a sudden, violent, involuntary contraction of a muscle or group of muscles. • Cyclobenzaprine (Flexeril) is the prototype for centrally acting muscle relaxants. • Centrally acting muscle relaxants do not act directly on painful muscles; rather, they work by their CNS depressant activity. • Most centrally acting muscle relaxants are not effective in treating spasticity. • In addition to their CNS depressant effects, centrally acting muscle relaxants have anticholinergic and antihistaminic effects. • Safety is a primary concern for patients receiving centrally acting muscle relaxants and spasmolytics. • Centrally acting muscle relaxants should be given with caution to older adults. They are not indicated for use in children. • Spasticity is a prolonged increased tone in muscles that may lead to contraction. • Baclofen (Lioresal) is the prototype centrally acting spasmolytic drug. • Gabapentin (Neurontin) is a miscellaneous antiepileptic drug that also has spasmolytic properties. • Dantrolene (Dantrium) is a peripherally acting spasmolytic that affects spasticity within the muscle fi bers. • Botulinum toxin type A (Botox) is used to manage chronic muscle spasms that do not respond to other treatment methods. It may also be used for cosmetic purposes. • Spasmolytics should be used cautiously in patients who require spasticity to remain upright.
UR - http://www.scopus.com/inward/record.url?scp=84971255230&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84971255230&partnerID=8YFLogxK
M3 - Chapter
AN - SCOPUS:84971255230
SN - 9781451187663
SP - 342
EP - 358
BT - Drug Therapy in Nursing
PB - Wolters Kluwer Health Adis (ESP)
ER -